Do you think there is any compelling data to support giving brentuximab as frontline therapy for pediatric patients with Hodgkin lymphoma?

Yes and no. It is clear that you can cure patients with pediatric HL without the use of brentuximab vedotin. While I believe it is safe and effective, if it is not covered by insurance, I would not advocate for its use in low and intermediate risk pediatric patients.

However, for HR pediatric patients, the results of HLHR13 were published in JCO this spring and demonstrate both the safety and efficacy of AEPA/CAPDac for high risk pediatric HL. 35% of patients received no radiation therapy and the...